IDH2 and acute myeloid leukemia: Among patients with ND IDH2mutAML, 5 (71%) were categorized as intermediate risk and two patients (29%) with adverse risk according to ELN 2017 [21]; all seven (100%) patients had AML with IDH2 p.R140Q with a median variant allele frequency (VAF) of 42% (range, 26–50%).